STOCK TITAN

BioCryst (BCRX) Chief R&D Officer receives large stock option and RSU inducement grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BioCryst Pharmaceuticals Chief R&D Officer Sandeep Menon received equity grants as part of his compensation. On April 6, 2026, he was granted 441,350 employee stock options for common stock at an exercise price of $9.47 per share, expiring in 2036.

He also received an inducement grant of 205,150 restricted stock units of common stock. Both the RSUs and the options vest or become exercisable in equal 25% installments on each of the first, second, third and fourth anniversaries of the grant date, aligning his incentives with longer-term company performance rather than reflecting open-market trading.

Positive

  • None.

Negative

  • None.
Insider Menon Sandeep
Role Chief R&D Officer
Type Security Shares Price Value
Grant/Award Emp. Stock Option (Right to Buy) 441,350 $0.00 --
Grant/Award Common Stock 205,150 $0.00 --
Holdings After Transaction: Emp. Stock Option (Right to Buy) — 441,350 shares (Direct); Common Stock — 205,150 shares (Direct)
Footnotes (1)
  1. Inducement grant of restricted stock units pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated (the "Stock Incentive Plan"), which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Inducement grant of employee stock options pursuant to the Stock Incentive Plan, which will become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.
Employee stock options granted 441,350 options Granted April 6, 2026 to Chief R&D Officer
Option exercise price $9.47/share Exercise price for 441,350 employee stock options
Option expiration April 6, 2036 Expiration date of employee stock options
Restricted stock units granted 205,150 RSUs Inducement grant of common stock RSUs
Vesting schedule 25% per year over 4 years Applies to both RSUs and stock options
restricted stock units financial
"Inducement grant of restricted stock units pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
employee stock options financial
"Inducement grant of employee stock options pursuant to the Stock Incentive Plan"
Employee stock options are contracts that give workers the right to buy a company's shares at a set price sometime in the future, like a coupon that lets you purchase stock at today’s price later on. Investors care because they align employees’ incentives with company performance and create a potential future claim on shares that can reduce existing owners’ percentage and add to a company’s reported compensation costs.
Stock Incentive Plan financial
"pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated"
A stock incentive plan is a company program that gives employees or directors pieces of ownership or the right to buy shares over time, similar to receiving a bonus paid in company stock instead of cash. Investors pay attention because these plans align staff incentives with long‑term company performance but can also dilute existing shareholders and affect reported profits when grants are expensed, so they influence both ownership percentages and financial results.
inducement grant financial
"Inducement grant of employee stock options pursuant to the Stock Incentive Plan"
An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Menon Sandeep

(Last)(First)(Middle)
4505 EMPEROR BLVD.
SUITE 200

(Street)
DURHAM NORTH CAROLINA 27703

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief R&D Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/06/2026A205,150(1)A$0205,150D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Emp. Stock Option (Right to Buy)$9.4704/06/2026A441,350(2) (2)04/06/2036Common Stock441,350$0441,350D
Explanation of Responses:
1. Inducement grant of restricted stock units pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated (the "Stock Incentive Plan"), which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
2. Inducement grant of employee stock options pursuant to the Stock Incentive Plan, which will become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.
/s/ Alane P. Barnes, by power of attorney04/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BioCryst (BCRX) Chief R&D Officer Sandeep Menon receive in this Form 4?

He received equity compensation grants, not open-market purchases. The filing shows 441,350 employee stock options at a $9.47 exercise price and 205,150 restricted stock units, all tied to BioCryst common stock and vesting over four years as part of his inducement package.

How many BioCryst (BCRX) stock options were granted to Sandeep Menon?

He was granted 441,350 employee stock options. These options give him the right to buy BioCryst common stock at $9.47 per share and expire in 2036, with 25% of the options becoming exercisable on each anniversary from the first through fourth years.

What restricted stock units did Sandeep Menon receive from BioCryst (BCRX)?

He received an inducement grant of 205,150 restricted stock units of common stock. These RSUs vest 25% on each of the first, second, third and fourth anniversaries of the grant date, effectively spreading the ownership benefits across a four-year service period.

Is Sandeep Menon buying or selling BioCryst (BCRX) shares in this filing?

He is not buying or selling in the market; this is a grant of equity compensation. The Form 4 reports awards of options and restricted stock units with zero purchase price, structured as inducement grants subject to a multi-year vesting and exercisability schedule.

Why are these BioCryst (BCRX) grants described as inducement awards?

They are characterized as inducement grants under the company’s Stock Incentive Plan. The footnotes state the RSUs and employee stock options were granted pursuant to BioCryst’s Stock Incentive Plan and structured to vest annually over four years, supporting executive recruitment and retention objectives.